Objective:

To evaluate the effectiveness of single fraction SBRT specifically for patients with peripherally located lung cancer.

Key Findings:

• One fraction of SBRT is as effective as three, four, or five fractions, with significant cost savings and convenience for patients.
• Single fraction treatment is significantly cheaper, costing about one-third of multiple fractions, which can alleviate financial toxicity.
• Single fraction SBRT reduces patient exposure to radiation and is more convenient, especially during the pandemic.

Interpretation:

The findings support the broader adoption of single fraction SBRT as a standard treatment for peripheral lung cancer, aligning with guidelines from major cancer organizations such as the National Comprehensive Cancer Network.

Limitations:

• The study's comparison with five fractions was not a prospective trial, which may limit the generalizability of the findings.
• Further research is needed to explore single fraction SBRT for other types of cancer and to validate these findings.

Conclusion:

Single fraction SBRT offers a cost-effective, convenient, and equally effective treatment option for lung cancer patients, likely leading to increased adoption in clinical practice and improved patient outcomes.